Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | ULK1 | O75385 | 8/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866839 | 0.88 | ROCK2 (0.55) | ROCK2ROCK1ITKULK1PDPK1 | |
| SCHEMBL13198194 | 0.82 | ROCK2 (0.51) | ROCK2ROCK1ITKULK1PDPK1 | |
| SCHEMBL2861604 | 0.74 | MAPK10 (0.67) | ROCK2ROCK1ITKPDPK1MAPK10 | |
| SCHEMBL2560944 | 0.72 | ROCK2 (0.67) | ROCK2ROCK1ULK1ACKR3 | |
| SCHEMBL12282076 | 0.72 | TTK (0.66) | ROCK2ROCK1 | |
| SCHEMBL173270 | 0.72 | MAPK1 (0.60) | ROCK2ROCK1MAPK3MAPK1MAP2K2 | |
| Hydrochloric Acid SCHEMBL2568328 | 0.71 | TTK (0.65) | ROCK2ROCK1 | |
| SCHEMBL15021912 | 0.71 | ROCK2 (0.68) | ROCK2ROCK1MAPK3MAPK1MAP2K2 | |
| SCHEMBL15022646 | 0.71 | ROCK2 (0.68) | ROCK2ROCK1MAPK3MAPK1MAP2K2 | |
| SCHEMBL2879616 | 0.70 | PDPK1 (0.56) | ITKULK1PDPK1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | ROCK2 805/4885ROCK1 504/4885ITK 3726/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | ROCK2 1152/4885ROCK1 709/4885ITK 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.